Literature DB >> 22436791

Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.

Anne Gry Bentzen1, Marianne G Guren, Eva H Wanderås, Gunilla Frykholm, Kjell M Tveit, Tom Wilsgaard, Olav Dahl, Lise Balteskard.   

Abstract

PURPOSE: To evaluate treatment results, elucidate whether national guidelines were followed, and identify areas demanding further treatment optimization. METHODS AND MATERIAL: Between July 2000 and June 2007, 328 patients were treated with curatively intended chemoradiotherapy (CRT) for nonmetastatic squamous cell carcinoma of the anal region, according to national treatment guidelines based on tumor stage.
RESULTS: Complete response after CRT was obtained in 87% of patients, rising to 93% after salvage surgery. Chemotherapy, elective irradiation of the groin and salvage surgery were performed to a lesser extent in elderly patients, mainly because of frailty and comorbidity. Recurrence occurred in 24% of the patients, resulting in a 3- and 5-year recurrence-free survival (RFS) of 79% and 74%, respectively. Locoregional recurrences dominated, most commonly in the primary tumor site. Recurrence was treated with curative intent in 45% of the cases. The 3- and 5-year overall survival were 79% and 66%, and cancer-specific survival (CSS) were 84% and 75%, respectively. The risk of adverse outcome increased significantly with more locally advanced tumors and for male gender in multivariable analyses for RFS and CSS.
CONCLUSIONS: The treatment results are in accordance with similar cohorts. The primary treatment control rate was high, but there was a significant risk of locoregional recurrence in advanced tumors. The loyalty to national guidelines was broad, although individual adjustments occurred. However, caution to avoid toxicity must not lead to inadequate treatment. Male gender seems to have inferior outcome.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22436791     DOI: 10.1016/j.ijrobp.2011.12.062

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials.

Authors:  Noam VanderWalde; Jennifer Moughan; Stuart M Lichtman; Reshma Jagsi; Matthew Ballo; Ari VanderWalde; Mohammed Mohiuddin; Neal J Meropol; Lisa Kachnic; Adam Berger; Jaffer Ajani; Rani Anne; Judith L Hopkins; Amit Arora; Joshua Meyer; Susannah G Ellsworth; R Jeffrey Lee; Nathan Green; Christopher H Crane
Journal:  J Geriatr Oncol       Date:  2021-10-27       Impact factor: 3.599

Review 2.  Anal cancer: are we making progress?

Authors:  Ajay Aggarwal; Simon Duke; Rob Glynne-Jones
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

3.  Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors.

Authors:  Espen Rusten; Bernt Louni Rekstad; Christine Undseth; Dagmar Klotz; Eivor Hernes; Marianne Grønlie Guren; Eirik Malinen
Journal:  Br J Radiol       Date:  2019-03-11       Impact factor: 3.039

4.  Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.

Authors:  Robert Glynne-Jones; David Sebag-Montefiore; Helen M Meadows; David Cunningham; Rubina Begum; Fawzi Adab; Kim Benstead; Robert J Harte; Jill Stewart; Sandy Beare; Allan Hackshaw; Latha Kadalayil
Journal:  Lancet Oncol       Date:  2017-02-11       Impact factor: 41.316

5.  Overview of Recent Trends in the Management of Metastatic Anal Cancer.

Authors:  Mahender Yellu; Ayham Deeb; Olugbenga Olowokure
Journal:  World J Oncol       Date:  2015-02-14

6.  Characteristics and survival of korean anal cancer from the Korea central cancer registry data.

Authors:  Hyoung-Chul Park; Kyu-Won Jung; Byung-Woo Kim; Aesun Shin; Young-Joo Won; Jae Hwan Oh; Seung-Yong Jeong; Chang Sik Yu; Bong Hwa Lee
Journal:  Ann Coloproctol       Date:  2013-10-31

7.  Management of two cases of recurrent anal carcinoma.

Authors:  Eiko Klimant; Maurie Markman
Journal:  Case Rep Oncol       Date:  2013-09-12

8.  Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China.

Authors:  Yong Lu; Xiaohao Wang; Peiyang Li; Tao Zhang; Jiaming Zhou; Yufeng Ren; Yi Ding; Haihua Peng; Qichun Wei; Kaiyun You; Jason J Ong; Christopher K Fairley; Andrew E Grulich; Meijin Huang; Yuanhong Gao; Huachun Zou
Journal:  BMC Cancer       Date:  2020-07-21       Impact factor: 4.430

9.  Patterns of recurrence in anal cancer: a detailed analysis.

Authors:  Martin P Nilsson; Erik D Nilsson; Anders Johnsson; Otilia Leon; Adalsteinn Gunnlaugsson; Jonas Scherman
Journal:  Radiat Oncol       Date:  2020-05-27       Impact factor: 3.481

10.  Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.

Authors:  Rebecca Shakir; Richard Adams; Rachel Cooper; Amy Downing; Ian Geh; Duncan Gilbert; Clare Jacobs; Christopher Jones; Cressida Lorimer; Wanangwa C Namelo; David Sebag-Montefiore; Paul Shaw; Rebecca Muirhead
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-17       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.